Acute myeloid leukemia-derived exosomes deliver miR-24-3p to hinder the T-cell immune response through DENN/MADD targeting in the NF-κB signaling pathways.
AML
Apoptosis
Immune response
T cells
miR-24-3p
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
21 09 2023
21 09 2023
Historique:
received:
08
06
2023
accepted:
07
08
2023
medline:
25
9
2023
pubmed:
22
9
2023
entrez:
22
9
2023
Statut:
epublish
Résumé
microRNAs (miRNAs) are known as potent gene expression regulators, and several studies have revealed the prognostic value of miRNAs in acute myeloid leukemia (AML) patient survival. Recently, strong evidence has indicated that miRNAs can be transported by exosomes (EXOs) from cancer cells to recipient immune microenvironment (IME) cells. We found that AML blast-released EXOs enhance CD3 T-cell apoptosis in both CD4 and CD8 T cells. We hypothesized that miRNAs present in EXOs are key players in mediating the changes observed in AML T-cell survival. We found that miR-24-3p, a commonly overexpressed miRNA in AML, was present in released EXOs, suggesting that EXO-miR-24-3p was linked to the increased miR-24-3p levels detected in isolated AML T cells. These results were corroborated by ex vivo-generated miR-24-3p-enriched EXOs, which showed that miR-24-3p-EXOs increased apoptosis and miR-24-3p levels in T cells. We also demonstrated that overexpression of miR-24-3p increased T-cell apoptosis and affected T-cell proliferation by directly targeting DENN/MADD expression and indirectly altering the NF-κB, p-JAK/STAT, and p-ERK signaling pathways but promoting regulatory T-cell (Treg) development. These results highlight a mechanism through which AML blasts indirectly impede T-cell function via transferred exosomal miR-24-3p. In conclusion, by characterizing the signaling network regulated by individual miRNAs in the leukemic IME, we aimed to discover new nonleukemic immune targets to rescue the potent antitumor function of T cells against AML blasts. Video Abstract.
Sections du résumé
BACKGROUND
microRNAs (miRNAs) are known as potent gene expression regulators, and several studies have revealed the prognostic value of miRNAs in acute myeloid leukemia (AML) patient survival. Recently, strong evidence has indicated that miRNAs can be transported by exosomes (EXOs) from cancer cells to recipient immune microenvironment (IME) cells.
RESULTS
We found that AML blast-released EXOs enhance CD3 T-cell apoptosis in both CD4 and CD8 T cells. We hypothesized that miRNAs present in EXOs are key players in mediating the changes observed in AML T-cell survival. We found that miR-24-3p, a commonly overexpressed miRNA in AML, was present in released EXOs, suggesting that EXO-miR-24-3p was linked to the increased miR-24-3p levels detected in isolated AML T cells. These results were corroborated by ex vivo-generated miR-24-3p-enriched EXOs, which showed that miR-24-3p-EXOs increased apoptosis and miR-24-3p levels in T cells. We also demonstrated that overexpression of miR-24-3p increased T-cell apoptosis and affected T-cell proliferation by directly targeting DENN/MADD expression and indirectly altering the NF-κB, p-JAK/STAT, and p-ERK signaling pathways but promoting regulatory T-cell (Treg) development.
CONCLUSIONS
These results highlight a mechanism through which AML blasts indirectly impede T-cell function via transferred exosomal miR-24-3p. In conclusion, by characterizing the signaling network regulated by individual miRNAs in the leukemic IME, we aimed to discover new nonleukemic immune targets to rescue the potent antitumor function of T cells against AML blasts. Video Abstract.
Identifiants
pubmed: 37735672
doi: 10.1186/s12964-023-01259-1
pii: 10.1186/s12964-023-01259-1
pmc: PMC10515055
doi:
Substances chimiques
NF-kappa B
0
MicroRNAs
0
MADD protein, human
0
Guanine Nucleotide Exchange Factors
0
Death Domain Receptor Signaling Adaptor Proteins
0
MIRN24 microRNA, human
0
Types de publication
Video-Audio Media
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
253Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Crohns Colitis. 2020 Nov 7;14(11):1619-1631
pubmed: 32343772
BMC Immunol. 2010 Jul 09;11:38
pubmed: 20618967
Immunity. 2009 Jan 16;30(1):80-91
pubmed: 19144316
Front Cell Dev Biol. 2021 Nov 01;9:731062
pubmed: 34790660
Oral Oncol. 2010 Mar;46(3):204-8
pubmed: 20138800
Anticancer Res. 2005 Nov-Dec;25(6A):3703-7
pubmed: 16302729
Oncogene. 2020 Jan;39(2):428-442
pubmed: 31485019
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385732
Semin Cell Dev Biol. 2017 Jul;67:23-28
pubmed: 27956165
Blood. 2009 Oct 29;114(18):3909-16
pubmed: 19710498
J BUON. 2018 Sep-Oct;23(5):1413-1419
pubmed: 30570867
Blood. 2009 Oct 29;114(18):3793-802
pubmed: 19724059
PLoS One. 2017 Mar 21;12(3):e0174368
pubmed: 28323882
FASEB J. 2021 Oct;35(10):e21916
pubmed: 34510546
Oncol Rep. 2015 Apr;33(4):1639-49
pubmed: 25672522
Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10746-51
pubmed: 19520829
PLoS One. 2015 Jul 02;10(7):e0131761
pubmed: 26134277
Semin Immunopathol. 2018 Sep;40(5):505-515
pubmed: 29869058
Cancer Discov. 2021 Apr;11(4):933-959
pubmed: 33811125
Clin Exp Immunol. 2001 Dec;126(3):403-11
pubmed: 11737054
Tumour Biol. 2015 May;36(5):3693-701
pubmed: 25725584
Hepatology. 2019 Jul;70(1):241-258
pubmed: 30854665
J Biol Chem. 2013 Nov 29;288(48):34343-51
pubmed: 24133215
Nat Rev Immunol. 2010 Feb;10(2):111-22
pubmed: 20098459
Oncogene. 2017 May 25;36(21):3048-3058
pubmed: 27991933
Int Immunopharmacol. 2016 May;34:244-249
pubmed: 26994448
Int J Mol Sci. 2017 Jul 31;18(8):
pubmed: 28758974
Cells. 2020 Sep 08;9(9):
pubmed: 32911844
Biomed Pharmacother. 2018 May;101:257-263
pubmed: 29494963
Front Immunol. 2022 Sep 16;13:913951
pubmed: 36189271
Oncol Lett. 2016 Dec;12(6):4937-4948
pubmed: 28105201
J Biol Chem. 1997 May 2;272(18):12069-75
pubmed: 9115275
Biochem Biophys Res Commun. 2013 Feb 15;431(3):610-6
pubmed: 23291181
Mol Ther. 2021 Sep 1;29(9):2723-2736
pubmed: 33905821
Immunol Cell Biol. 2015 Sep;93(8):753-64
pubmed: 25735723
Int J Mol Sci. 2020 Sep 25;21(19):
pubmed: 32992819
Mol Ther. 2020 Sep 2;28(9):1953-1964
pubmed: 32563274
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4210-5
pubmed: 15007167
Front Genet. 2020 Jul 17;11:700
pubmed: 32765582
J Cell Physiol. 2020 Feb;235(2):691-705
pubmed: 31328284
Pathobiology. 2015;82(2):68-75
pubmed: 26045155
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
J Pathol. 2016 Nov;240(3):329-340
pubmed: 27538493
Front Oncol. 2018 Jun 13;8:213
pubmed: 29951373
Future Oncol. 2017 Dec;13(28):2583-2592
pubmed: 29198150
Cancer Lett. 2020 Jul 10;482:33-43
pubmed: 32289440
PLoS One. 2016 Apr 14;11(4):e0153682
pubmed: 27077371
FEBS J. 2011 Apr;278(6):862-76
pubmed: 21232017